Charbel Moussa discusses his exciting work into the use of FDA approved tyrosine kinase inhibitors to clear toxic neuronal proteins via autophagy.
Browsing: Parkinson’s disease
A recent investigation suggests that a drug commonly used to treat liver disease – ursodeoxycholic acid – could slow the progression of Parkinson’s disease.
Recently developed monoclonal antibodies have been demonstrated to successfully target toxic oligomer proteins in both Alzheimer’s and Parkinson’s disease.
New study highlights the potential efficacy of existing antimalarial drugs as a treatment for Parkinson’s.
International Stem Cell Corporation develops an alternative stem cell treatment for Parkinson’s disease
ISCO develop a parthenogenesis stem cell technology which could potentially avoid the limiting immune-response issues in regenerative medicine.
Arthur Roach, Research and Development Director at Parkinson’s UK, speaks to Neurology Central to discuss recent progress and current challenges involved in Parkinson’s research. In particular, we discuss the status of the anticipated glial cell-derived neurotrophic factor study.
Striving for ‘best health’: driving up the standard of services for Parkinson’s disease patients in the UK
Neurology Central talks to David Burn, Clinical Director at Parkinson’s UK, to discuss the recently launched Parkinson’s Excellence Network, and the future of Parkinson’s disease treatment and care in the UK.
This review is a concise summary of nonmotor symptoms in both genetic and idiopathic Parkinson’s disease patients, highlighting the importance of nonmotor symptoms in research and clinical practice of Parkinson’s disease together with some of the potential differences in pathophysiology and clinical features.